Literature DB >> 14700605

Part II: Hodgkin's lymphoma--diagnosis and treatment.

Volker Diehl1, Roman K Thomas, Daniel Re.   

Abstract

The outcome of patients with all stages of Hodgkin's lymphoma has improved dramatically over the past few decades. This is mainly due to the use of risk-adapted therapies using intensive polychemotherapeutic regimens in combination with other modalities. Patients with early favourable or unfavourable (intermediate) stage disease receive two or four cycles of chemotherapy, respectively, followed by involved-field radiotherapy (20-30Gy). Advanced stage Hodgkin's lymphoma is treated more aggressively using six to eight cycles of chemotherapy but the effectiveness of consolidative radiotherapy for patients who show a complete response after chemotherapy alone is still unknown. The main challenge in the near future will be the development of strategies that decrease late morbidity and mortality but retain the same efficacy of current regimens. In this paper we review current diagnostic techniques and management strategies used to treat Hodgkin's lymphoma, and the range of new modalities being used to improve long-term outcome and patient quality of life.

Entities:  

Mesh:

Year:  2004        PMID: 14700605     DOI: 10.1016/s1470-2045(03)01320-2

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  32 in total

1.  Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.

Authors:  Anas Younes; Yasuhiro Oki; Peter McLaughlin; Amanda R Copeland; Andre Goy; Barbara Pro; Lei Feng; Ying Yuan; Hubert H Chuang; Homer A Macapinlac; Fredrick Hagemeister; Jorge Romaguera; Felipe Samaniego; Michelle A Fanale; Bouthaina Shbib Dabaja; Maria A Rodriguez; Nam Dang; Larry W Kwak; Sattva S Neelapu; Luis E Fayad
Journal:  Blood       Date:  2012-02-27       Impact factor: 22.113

2.  The Dark Side of the Moon - the Side Effects of Therapy in a Dynamic Era of Breast Cancer Management.

Authors:  Richard Greil
Journal:  Breast Care (Basel)       Date:  2009-06-26       Impact factor: 2.860

Review 3.  Modulation of cardiovascular toxicity in Hodgkin lymphoma: potential role and mechanisms of aerobic training.

Authors:  Anthony F Yu; Lee W Jones
Journal:  Future Cardiol       Date:  2015-08-03

4.  Radiation-induced spinal cord glioma subsequent to treatment of Hodgkin's disease: case report and review.

Authors:  Laurent Riffaud; Marc Bernard; Thierry Lesimple; Xavier Morandi
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

Review 5.  Hodgkin's lymphoma.

Authors:  Amin Rahemtulla; Evangelos Terpos
Journal:  BMJ Clin Evid       Date:  2009-06-15

6.  Report on trends of incidence (1970-2002) of and mortality (1952-2002) from cancer in Germany.

Authors:  Nikolaus Becker; Hans-Peter Altenburg; Christa Stegmaier; Hartwig Ziegler
Journal:  J Cancer Res Clin Oncol       Date:  2006-08-03       Impact factor: 4.553

7.  Tissue-microarray based immunohistochemical analysis of survival pathways in nodular sclerosing classical Hodgkin lymphoma as compared with Non-Hodgkin's lymphoma.

Authors:  Jitakshi De; Robert E Brown
Journal:  Int J Clin Exp Med       Date:  2010-01-30

8.  Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma.

Authors:  Vincent Camus; Aspasia Stamatoullas; Sylvain Mareschal; Pierre-Julien Viailly; Nasrin Sarafan-Vasseur; Elodie Bohers; Sydney Dubois; Jean Michel Picquenot; Philippe Ruminy; Catherine Maingonnat; Philippe Bertrand; Marie Cornic; Valérie Tallon-Simon; Stéphanie Becker; Liana Veresezan; Thierry Frebourg; Pierre Vera; Christian Bastard; Hervé Tilly; Fabrice Jardin
Journal:  Haematologica       Date:  2016-06-13       Impact factor: 9.941

Review 9.  The biology of Hodgkin's lymphoma.

Authors:  Ralf Küppers
Journal:  Nat Rev Cancer       Date:  2008-12-11       Impact factor: 60.716

10.  Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling.

Authors:  Martin Peifer; Jonathan Weiss; Martin L Sos; Mirjam Koker; Stefanie Heynck; Christian Netzer; Stefanie Fischer; Haridas Rode; Daniel Rauh; Jörg Rahnenführer; Roman K Thomas
Journal:  PLoS One       Date:  2010-01-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.